

ASX ANNOUNCEMENT

5 December 2025

Completion of Sale of Clermont Gold Project

- Completion of sale of the Clermont Gold Project to Moonlight Resources Limited under terms previously announced
- Diatreme receives \$3.25m in Moonlight shares and \$250,000 cash as consideration
- Diatreme to become a significant shareholder in Moonlight upon completion of Moonlight's IPO, expected next week
- Right retained by Diatreme to appoint a nominee director to the Moonlight Board

Silica Sands developer and explorer **Diatreme Resources Limited** ("Diatreme," ASX:DRX) advises that it has today completed the sale of all the issued capital in Chalcophile Resources Pty Ltd ("Chalcophile") and PGE Minerals Pty Ltd (PGE Minerals) the entities which hold the Clermont Gold Project, to Moonlight Resources Limited ("Moonlight"), in accordance with the Share Sale Agreement dated 28 October 2025.

The transaction formally completed on the terms previously disclosed to the market, including:

- Issue to Diatreme of 16,250,000 ordinary shares in Moonlight, valued at A\$3.25 million under Moonlight's IPO prospectus;
- Cash consideration of A\$250,000 paid to Diatreme; and
- Diatreme becoming a significant shareholder of Moonlight on completion of its IPO and retaining the right to appoint a nominee director to the Moonlight board.

The completion of the transaction forms part of Moonlight's proposed initial public offering and ASX listing. Moonlight has lodged its IPO Prospectus with ASIC, and Diatreme has been advised that Moonlight's admission to the Official List and commencement of trading is expected next week.

This announcement is authorised for release by the Board.

Neil McIntyre
Chief Executive Officer

Wayne Swan
Chairman

Contact – Mr Neil McIntyre - Ph – +61 (0)7 3397 2222
Website - www.diatreme.com.au

+61 7 3397 2222

Unit 8, 55–61 Holdsworth St
Coorparoo, Qld, 4151

diatreme.com.au

AUSTRALIAN SANDS. UNIVERSAL DEMAND.



Email - manager@diatreme.com.au

For investor/media queries, please contact:

Anthony Fensom, Fensom Advisory

anthony@fensom.com.au

Ph: +61 (0)407 112 623

For personal use only